Apogee Therapeutics, Inc. — Form 8-K
Filed August 10, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 95/100
What the filing says
AbbVie agreed in June 2026 to acquire all outstanding Apogee shares for $135.11 per share in cash, totaling approximately $10.9 billion in equity value. The transaction is expected to close in Q3 2026, subject to shareholder approval and regulatory clearance. Concurrently, Apogee received $1.3 billion in non-dilutive financing from Blackstone Life Sciences in May 2026 to fund Phase 3 development of zumilokibart; the company reported positive Phase 2 APEX Part B results (65.9% EASI-75 response at mid-dose) supporting planned Phase 3 advancement in atopic dermatitis.
Why this rating
Acquisition price of $10.9B equals ~606% of Apogee's $1.8B market cap—a transformational exit event. Pending close and regulatory risk remain, but deal materially alters shareholder outcomes and company trajectory.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.